… -length monoclonal antibodies. Most of the current COVID-19 antibody therapeutic candidates
in … therapeutic antibodies are in discovery or preclinical studies. As of 8 August 2020, eight …

… -2 and subsequent COVID-19 pandemic … therapeutic strategies. In this article, we review
the role of SARS-CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 …

… In this article, we review seven existing SARS-CoV-2 antibody therapeutic candidates
from the literature. As molecular structures are able to reveal the molecular mechanism of …

… Here, we discuss some of the most active areas of developing strategies to treat COVID-19, …
antibodies against SARS-CoV-2 for prophylactic and therapeutic treatment of COVID-19. …

… antibody based therapeutic intervention for COVID-19 by considering the existing knowledge
on the neutralizing monoclonal antibodies … antiviral monoclonal antibody therapeutics. Nat …

… of novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS… therapeutic
intervention against COVID-19, no therapeutic agent has been approved for treating COVID-19 …

… anti-coronavirus activities. We also discuss the lessons learned from COVID-19 and other
infectious diseases with regard to drug repurposing strategies, pan-coronavirus drug targets, …

… all aspects of COVID-19 therapeutics. We explore challenges that have stymied COVID-19
drug development and highlight important unmet needs. We examine key therapeutic classes …

… of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19
antibody … -19 antibody therapeutics tracker is a very good attempt and example to this challenge …

… In this mini-review, we highlight the therapeutic intervention … antibodies can target a common
epitope on these viruses and offers potential for the prevention and treatment of COVID-19. …